Internationally-driven award-winning professional with experience in developing markets in Canada, Europe and Latin America. I have experience in sales, training, marketing, management and have strong analytical and problem solving skills, clear & concise communication skills (spoken and written), people skills and excellent attention to detail and sense of priorities. I am dynamic, proactive, dedicated, creative, results-driven, adaptable, ambitious, independent, positive and determined. Teamwork and leadership are important to me, and I truly enjoy working with teams from different countries, cultures & languages. I am trilingual (English, French & Spanish), currently learning Portuguese and beginner level in German. I am passionate and eager to learn. My desire is to work in Europe for an international company in which I could bring forth my skill sets and dedication.
As a consultant, I provided support and specialized training to specialists (Interventional Neuro-Radiologists or 'INRs') for both Neuro and Peripheral EV3 endovascular products portfolio in Latin America
Developed and was the 'go-to person' for the EMEA and Brazil markets for a high-tech revolutionary endovascular device (Pipeline Embolization Device or "PED") through clinical support, case coordination and specialized training to specialists (>100) and sales teams. Also developed, implemented and ensured compliance of a specific sales process ensuring best possible patient outcome and resulting in exponential market growth.
Developed new and effective marketing materials and provided specialized support to the EU salesteams as the International Marketing Product Manager for the "PED".
Exceeded revenue goals achieving over 136% of sales over quota (36M EUR) and contributed to the company’s most successful product launch.
Built very strong influential business relationships with the world's top INR specialists.
Company Description
EV3 was headquartered in Plymouth Minn., founded in 2000 with over 1,350 employees, maker of stents and other endovascular medical devices. It reported $449.1 million in revenue and $41.9 million in profit in 2010. EV was acquired by Covidien in 2010 for 2.6B US$.